Atopic dermatitis

A recent study found no significant association between moderate-to-severe atopic dermatitis and the incidence of non-alcoholic fatty liver disease. Atopic dermatitis (AD) is an inflammatory skin disease affecting approximately 20% of children and 2–8% of adults. Some studies have linked AD to metabolic syndrome. As metabolic syndrome is associated with non-alcoholic fatty liver disease (NAFLD),...

Topical treatment containing xyloglucan and pea protein was found to be a safe and effective steroid-sparing alternative for children with atopic dermatitis in a recent study. Atopic dermatitis (AD) is a chronic inflammatory skin condition primarily affecting children. Topical corticosteroids are the main treatment used to control skin inflammation and flare-ups in the pediatric population...

A phase III trial found that long-term dupilumab treatment demonstrated acceptable safety and sustained efficacy in children aged 6–11 years with severe atopic dermatitis. Atopic dermatitis (AD) is the most prevalent inflammatory skin disease in children. Treatment options are limited in children aged 6–11 years with severe AD inadequately controlled by topical therapies. Dupilumab has...

If you live with atopic dermatitis, knowing about the treatment options and their effectiveness can be helpful when you discuss your treatment needs with your healthcare provider to determine the right one for you. A recent study about systemic therapies offers insight for those seeking relief. Systemic therapies don’t always provide complete relief from atopic...

Recent research has explored how biologics used to treat atopic dermatitis might increase the risk of developing conjunctivitis. If you have atopic dermatitis and are considering biologic medications, this overview may help you understand potential risks and what to expect. Certain treatments for atopic dermatitis may raise the chance of getting conjunctivitis. The primary treatments...

Greater improvement seen in disease severity by 12 weeks with ciclosporin, but MTX was superior by 60 weeks For children and young people with severe atopic dermatitis (AD), ciclosporin (CyA) and methotrexate (MTX) are both effective over 36 weeks, according to a study published online Sept. 19 in the British Journal of Dermatology. Carsten Flohr, Ph.D.,...

Over-the-counter 1% colloidal oatmeal cream effectively treats mild-to-moderate atopic dermatitis in Black children, according to a recent study. Atopic dermatitis (AD) is one of the most common skin conditions among children in the United States. Its prevalence varies with race and ethnicity, with Black children being 1.7 times more likely to develop AD than White...

Patient race and specific atopic dermatitis diagnoses are associated with differences in dupilumab prescription patterns. Atopic dermatitis (AD) is a common chronic inflammatory disease. Treatment with a systemic immunomodulating agent is indicated in moderate-to-severe AD. These systemic agents include cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, and systemic steroids. Dupilumab, a fully human monoclonal antibody, may be...

Atopic dermatitis severity and treatment patterns do not differ among diverse racial and ethnic groups in the United States, according to a recent study. Atopic dermatitis (AD) has heterogeneous manifestations across regional and racial groups. Previous studies in the United States found racial and ethnic differences in AD disease patterns, including risk factors for severity,...